Alnylam Huntington's drug shows early promise in Phase 1 study

Alnylam Pharmaceuticals reported early-stage data suggesting its investigational RNAi therapy may slow Huntington's disease progression. The results are preliminary and unconfirmed, but they add momentum to a competitive therapeutic landscape. The key uncertainty is whether the drug will demonstrate meaningful clinical benefit in larger trials.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works